These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10949676)

  • 21. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Overgaard J; Horsman MR
    Int J Hyperthermia; 2001; 17(6):508-19. PubMed ID: 11719967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
    Iversen AB; Busk M; Horsman MR
    Acta Oncol; 2013 Oct; 52(7):1320-6. PubMed ID: 23988183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.
    Zhao D; Chang CH; Kim JG; Liu H; Mason RP
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):574-81. PubMed ID: 21345614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
    Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
    Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors.
    Eikesdal HP; Bjerkvig R; Mella O; Dahl O
    Radiother Oncol; 2001 Aug; 60(2):147-54. PubMed ID: 11439209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
    Horsman MR; Ehrnrooth E; Ladekarl M; Overgaard J
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):895-8. PubMed ID: 9845117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo.
    Overgaard J; Radacic MM; Grau C
    Cancer Res; 1991 Jan; 51(2):707-11. PubMed ID: 1985787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.
    Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Ley CD; Kristjansen PE; Horsman MR
    Acta Oncol; 2010 Oct; 49(7):906-13. PubMed ID: 20831477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.
    Kragh M; Quistorff B; Horsman MR; Kristjansen PE
    Neoplasia; 2002; 4(3):263-7. PubMed ID: 11988846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
    Li L; Rojiani A; Siemann DW
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):899-903. PubMed ID: 9845118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation.
    Horsman MR
    Int J Hyperthermia; 2015; 31(5):453-9. PubMed ID: 25915829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy.
    Faustino C; Francisco AP; Isca VMS; Duarte N
    Curr Pharm Des; 2018; 24(36):4270-4311. PubMed ID: 30636588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo.
    Jordan A; Scholz R; Wust P; Fähling H; Krause J; Wlodarczyk W; Sander B; Vogl T; Felix R
    Int J Hyperthermia; 1997; 13(6):587-605. PubMed ID: 9421741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
    Horsman MR; Murata R
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1047-55. PubMed ID: 14575836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.
    Wildiers H; Ahmed B; Guetens G; De Boeck G; de Bruijn EA; Landuyt W; van Oosterom AT
    Eur J Cancer; 2004 Jan; 40(2):284-90. PubMed ID: 14728944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biology of the combretastatins as tumour vascular targeting agents.
    Tozer GM; Kanthou C; Parkins CS; Hill SA
    Int J Exp Pathol; 2002 Feb; 83(1):21-38. PubMed ID: 12059907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
    Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
    Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues.
    Fisker RV; Horsman MR; Overgaard J
    Acta Oncol; 1991; 30(5):641-7. PubMed ID: 1892683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting tumour vasculature: the development of combretastatin A4.
    Griggs J; Metcalfe JC; Hesketh R
    Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.